

## A simple protein-based SARS-CoV-2 surrogate neutralization assay

### Authors

Kento T. Abe<sup>1,2,\*</sup>, Zhijie Li<sup>1\*</sup>, Reuben Samson<sup>1,2</sup>, Payman Samavarchi-Tehrani<sup>2</sup>, Emelissa J. Valcourt<sup>3</sup>, Heidi Wood<sup>3</sup>, Patrick Budylowski<sup>4,5</sup>, Alan Dupuis<sup>6</sup>, Roxie C. Girardin<sup>6</sup>, Bhavisha Rathod<sup>2</sup>, Karen Colwill<sup>2</sup>, Allison J McGeer<sup>7,8,9</sup>, Samira Mubareka<sup>10</sup>, Jennifer L. Gommerman<sup>4</sup>, Yves Durocher<sup>11</sup>, Mario Ostrowski<sup>4,12,13</sup>, Kathleen A. McDonough<sup>6,14</sup>, Michael A. Drebot<sup>3,15</sup>, Steven J. Drews<sup>16</sup>, James M. Rini<sup>1,17\*</sup> and Anne-Claude Gingras<sup>1,2\*</sup>

### Affiliations

<sup>1</sup> Department of Molecular Genetics, University of Toronto, Toronto, ON, Canada

<sup>2</sup> Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada

<sup>3</sup> Zoonotic Diseases and Special Pathogens, National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB, Canada

<sup>4</sup> Department of Immunology, University of Toronto, Toronto, ON, Canada

<sup>5</sup> Institute of Medical Science, University of Toronto, Toronto, ON, Canada

<sup>6</sup> Wadsworth Center, New York State Department of Health, 120 New Scotland

<sup>7</sup> Department of Microbiology, at Mount Sinai Hospital, Sinai Health System, Toronto, ON, Canada

<sup>8</sup> Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada

<sup>9</sup> Faculty of Medicine, University of Toronto, Toronto, ON, Canada

<sup>10</sup> Department of Laboratory Medicine and Molecular Diagnostics, Division of Microbiology, Sunnybrook Health Sciences Centre, Toronto, ON, Canada; Biological Sciences, Sunnybrook Research Institute, Toronto, ON, Canada; Division of Infectious Diseases, Sunnybrook Health Sciences Centre; Department of Laboratory Medicine and Pathobiology, University of Toronto.

<sup>11</sup> Mammalian Cell Expression, Human Health Therapeutics Research Centre, National Research Council Canada, Montréal, QC, Canada

<sup>12</sup> Department of Medicine, University of Toronto, Toronto, ON, Canada

<sup>13</sup> Li Ka Shing Knowledge Institute, St. Michael's Hospital, Toronto, ON, Canada

<sup>14</sup> Department of Biomedical Sciences, School of Public Health, University at Albany, SUNY, Albany, NY, USA 12201, USA Avenue, PO Box 22002, Albany, NY 12201-2002, USA.

<sup>15</sup> Department of Medical Microbiology and Infectious Disease, University of Manitoba, MA, Canada

<sup>16</sup> Canadian Blood Services, Edmonton, AB & Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada

<sup>17</sup> Department of Biochemistry, University of Toronto, Toronto, ON, Canada

• These authors contributed equally

\* Correspondence: [james.rini@utoronto.ca](mailto:james.rini@utoronto.ca) and [gingras@lunenfeld.ca](mailto:gingras@lunenfeld.ca)

### Abstract

With the COVID-19 pandemic surpassing 12M confirmed cases and 550K deaths worldwide, defining the key components of the immune response to SARS-CoV-2 infection is critical. Of particular importance is the identification of immune correlates of infection that would support public health decision-making on treatment approaches, vaccination strategies, and convalescent plasma therapy. While ELISA-based assays to detect and quantitate antibodies to SARS-CoV-2 in patient samples have been developed, the detection of neutralizing antibodies typically requires more demanding cell-based viral assays. Here, we present and validate a safe and efficient protein-based assay for the detection of serum and plasma antibodies that block the interaction of the SARS-CoV-2 spike (S) protein receptor binding domain (RBD) with its receptor, angiotensin converting-enzyme

2 (ACE2). This test is performed on the same platform and in parallel with an enzyme-linked immunosorbent assay (ELISA) for the detection of antibodies against the RBD and serves as a surrogate neutralization assay.

## Main text

SARS-CoV-2 enters the host cell through the interaction of the viral spike (S) protein receptor binding domain (RBD) and the host cell receptor, angiotensin-converting enzyme 2 (ACE2)<sup>1</sup> (**Fig. 1a**), and antibodies that block this interaction have neutralizing potential. The detection and study of neutralizing antibody activity following natural infection (or vaccination) can support research aimed at the development of novel therapeutics and vaccine candidates. It can also aid in the identification of acceptable donors for convalescent plasma therapy<sup>2</sup>, and more generally to establish immune correlates of infection.

For SARS-CoV-2, viral neutralization assays are performed using either live virus<sup>3</sup> or viral vectors pseudotyped with the spike protein<sup>4</sup>. However, these cell culture-based assays are challenging to implement and time-consuming to run, factors that limit scalability. The conventional plaque reduction neutralization test (PRNT) that uses live SARS-CoV-2 virus is further complicated by the need for containment level 3 (CL-3) and a specialized laboratory set-up. Although the pseudotyped viral-vector-based assays do not require BSL-3 containment<sup>4</sup>, they are nevertheless complicated multistep procedures<sup>5</sup>.

By contrast, the detection and quantitation of polyclonal (neutralizing and non-neutralizing) antigen-specific antibodies in patient samples can be easily assayed by enzyme-linked immunosorbent assays (ELISA<sup>6</sup>). An ELISA is performed by immobilizing recombinantly produced viral antigen (such as the spike trimer or RBD; **Supplementary Fig. 1, 2**; see Methods) onto multi-well plastic plates that are then incubated with diluted patient serum or plasma samples. The detection of antibodies that bind to the antigen involves a second incubation with enzyme-conjugated anti-human antibodies, where the enzyme is often horseradish peroxidase (HRP). This enables the detection of a color change when an HRP substrate such as 3,3',5,5'-tetramethylbenzidine (TMB) is used. In direct binding assays of this type (**Fig. 1b**), the presence of patient antibodies against the viral antigen leads to a dose-dependent increase in the signal observed.

Here, we describe a modified ELISA-type assay that replaces the HRP-coupled anti-human antibody used in the direct binding assay with recombinantly-expressed soluble biotinylated ACE2. Streptavidin-poly HRP detection is then used to detect the association of ACE2-biotin to the immobilized RBD or spike trimer (**Fig. 1b - competition assay**). In this competition assay, the presence of patient antibodies that can block the binding of soluble ACE2 to the immobilized RBD leads to a dose-dependent decrease in the signal observed. In our hands, the configuration described is more sensitive than that of the reverse where immobilized ACE2 is detected by biotinylated RBD as in <sup>7</sup> (**Supplementary Fig. 3**). Moreover, with the RBD immobilized, the same overall protocol and colorimetric detection can be used for both the direct binding and competition ELISA assays thereby facilitating a direct comparison.

Although the competition assay worked well with either the RBD or the spike ectodomain trimer immobilized (**Fig 1c; Supplementary 4a**), we focused on the RBD as it is easier to produce and provides a simple one-to-one binding interaction with ACE2. Using a small test set (**Supplementary Fig. 4b**), we first showed that the serum/plasma from positive, but not negative control patients, inhibited the interaction between ACE2 and the immobilized RBD (**Fig. 1d**). The technical reproducibility of the assay was within 5–10% CV. The total time required to perform the assay (once the plates are coated with the antigen) is 3.5–4 hours and the assay can be performed using the same equipment and biosafety protocols as a standard ELISA.

Using both the competition and direct binding (with a dilution series) ELISA assays, we then profiled a set of 58 serum samples acquired at the Canadian Blood Services as part of a screen for convalescent plasma therapy donors (**Fig. 2a; Supplementary Fig. 5–7; Supplementary Table 1**). With reference to the direct binding results,

the competition ELISA showed that samples with high levels of IgG against the RBD were typically the most potent at blocking the RBD-ACE2 interaction (e.g. CBS13, which is included as a positive control). Conversely, samples lacking detectable RBD-binding antibodies were not able to block the interaction (**Fig. 2b**; **Supplementary Fig. 8**).

To more systematically evaluate the relationship between the RBD-binding antibody levels and the ability to block the RBD-ACE2 interaction (as determined by the competition ELISA), we calculated the area under the curve (AUC) for both assays and plotted the RBD-binding AUC versus the competition AUC (**Fig. 2c**; **Supplementary Fig. 9**). The plot showed a clear correlation ( $R^2 = 0.823$ ), with the sera containing the highest RBD-binding antibody levels being the most effective at blocking the RBD-ACE2 interaction (**Fig. 2c**; also compare **Fig. 2b** to **2a**; **Supplementary Table 1**). Nevertheless, there are samples with similar RBD-binding antibody concentrations that differ significantly in their ability to block the RBD-ACE2 interaction (**Fig. 2d**; **Supplementary Fig. 10**). Among samples, differences in antibody affinities and their abundance, as well as the RBD epitopes bound, are all factors that could explain these outliers.

While it is reasonable to expect that antibodies that block the RBD-ACE2 interaction would be neutralizing, we validated this using cell-based viral infectivity and entry assays. Fifty-seven of the 58 samples analyzed by the competition ELISA were analyzed by PRNT, the gold standard in the field. PRNT50 is defined as the concentration of patient serum/plasma capable of reducing the formation of viral plaques by 50% (PRNT90 is the concentration that reduces plaque formation by 90%). As shown in **Fig. 2e**, most of the samples displaying high values in the direct binding and competition ELISA assays were also positive by PRNT90 (and those with low titers were negatives). Both ELISA assays also gave an overall agreement with the PRNT50 titers and the titers obtained with the spike-pseudotyped lentiviral-based entry assay<sup>4</sup> (also see **Supplementary Fig. 11-12**). Taken together, these results indicate that our competition ELISA is a good surrogate neutralization assay, particularly for distinguishing between samples with high versus low neutralization activity. As such, the assay should be of value in the selection of candidate donors for convalescent plasma therapy and for monitoring immune correlates of patient outcomes. Future work will focus on providing a better understanding of the outliers observed in the both competition and neutralization assays. Indeed, rare but potent neutralizing antibodies in patient samples with low pseudovirus neutralization titers have recently been reported<sup>8</sup>.

To assess whether our competition ELISA might also be of value for screening the neutralization potential of monoclonal antibodies, we tested it using a number of neutralizing and non-neutralizing monoclonal antibodies and compared the results with that obtained in the cytopathic effect-reduction neutralization or lentiviral-based entry assay. As expected, the llama VHH72 monoclonal antibody previously shown to neutralize SARS-CoV-2 entry<sup>9</sup> (expressed here as an human Fc fusion construct) and the Active Motif 414-1 antibody first isolated in a convalescent patient and demonstrated to be neutralizing<sup>10</sup> both exhibited strong competition activity and neutralized the entry of spike pseudotyped lentivirus (**Fig. 2f**; **Supplementary Fig. 13-14**). A negative control IgG had no effect. In contrast, other antibodies such as an IgG derived from the monoclonal anti-SARS1 CR3022 or a commercial antibody from Genscript had a much more moderate effect, both in the competition assay (**Supplementary Fig. 15**) and either the cytopathic effect-reduction neutralization or lentiviral assays (**Supplementary Fig. 14, 16**). Notably, the Active Motif 414-2 antibody that bound efficiently to the RBD but that did not block the RBD-ACE2 interaction effectively and only partially prevent entry in the lentivirus entry assay (this antibody was previously shown to be incapable of neutralizing live SARS-CoV-2 virus<sup>4, 10</sup>). Taken together, these observations suggest that our competition assay is a good complement to more complex cell-based assays for the discovery/screening of neutralizing monoclonal antibodies.

In summary, we have developed a simple and safe competition ELISA that serves as a surrogate neutralization assay. It can be readily incorporated into existing testing platforms and may be of particular value in the selection of donors for convalescent plasma therapy and as a means of monitoring the immune response to

vaccination. Given that neutralizing antibody titres have recently been shown to wane rapidly, the assay may also be useful for broad serosurveillance<sup>11</sup>. When coupled with epidemiological studies, it might also be used to assess the risk of infection/re-infection. Finally, we note that the optimized conditions used here for the direct RBD-binding ELISA are very similar to those reported by the Krammer lab using RBD-expression constructs that have been widely distributed. Their RBD can be obtained from BEI resources<sup>6</sup>, and we found that it generates similar results when used with our biotinylated ACE2 in the competition assay (**Supplementary Fig. 17**). This should further facilitate the broad implementation of our assay across multiple laboratories.

### **Acknowledgements**

We thank Janet McManus at Canadian Blood Services for her technical and logistical expertise and the Wadsworth Center Media and Tissue Culture Core. We thank Joan Wither for the lupus patient samples, and Jesse Bloom and Katharine Crawford for sharing protocols and reagents for the lentiviral S pseudotyping assay. The following reagent was produced by Florian Krammer's group under HHSN272201400008C and obtained through BEI Resources, NIAID, NIH: Spike Glycoprotein Receptor Binding Domain (RBD) from SARS-Related Coronavirus 2, Wuhan-Hu-1, Recombinant from HEK293 Cells, NR-52306. We thank Matthew Stuitable and Alex Pelletier (NRC) for VHH72hFc1X7 expression and purification and Joe Schrag (NRC) for SEC-UPLC/MALS analysis. Funding for the development of the assays in the Gingras lab was provided through generous donations from the Royal Bank of Canada (RBC), Questcap and the Krembil Foundation to the Sinai Health System Foundation. We also acknowledge an "Ontario Together" team grant from the Government of Ontario to JG, JMR, ACG, MO, AM to develop serology and saliva assays. The equipment used is housed in the Network Biology Collaborative Centre at the Lunenfeld-Tanenbaum Research Institute, a facility supported by Canada Foundation for Innovation funding, by the Ontarian Government and by Genome Canada and Ontario Genomics (OGI-139). We also acknowledge funding support from New York State Department of Health (to KAM).

JMR is supported by the Canadian Institutes of Health Research (FRN 162305)

ACG is supported by the Canadian Institutes of Health Research (CIHR FDN 143301) and a Canada Research Chair, Tier 1, in Functional Proteomics.

### **Author contributions**

KTA and ACG designed the protein competition assay and the direct RBD antibody assay

ZL and JMR designed the protein expression, biotinylation and purification procedures

RS and PST optimized the lentiviral pseudotyping assay

EJM, HW, MAD, AD, RG, KAM, PB and MO developed, performed and analyzed the PRNT and/or cytopathic effect-reduction neutralization assays

KTA and BR performed direct ELISA experiments

YD designed the VHH72hFc1X7 construct, expression and purification procedures

KC helped coordinate the project

SD provided samples, coordinated neutralization testing and integrated PRNT and protein competition data

KTA and ACG analyzed the protein competition data

JLG, AJM, SM, MO and SD contributed essential patient samples

KTA, JMR and ACG wrote the manuscript with input from all authors


### **Conflict of interest statement**

Steven J Drews has acted as a content expert for respiratory viruses for Johnson & Johnson (Janssen). Work in the Gingras lab was partially funded by a contribution from QuestCap through the Sinai Health Foundation. The other authors declare no relevant conflicts of interest.


## References

1. Hoffmann, M. et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. *Cell* **181**, 271-280 e278 (2020).
2. Bloch, E.M. et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. *J Clin Invest* **130**, 2757-2765 (2020).
3. Mendoza, E.J., Manguiat, K., Wood, H. & Drebot, M. Two Detailed Plaque Assay Protocols for the Quantification of Infectious SARS-CoV-2. *Curr Protoc Microbiol* **57**, ecpmc105 (2020).
4. Crawford, K.H.D. et al. Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays. *Viruses* **12** (2020).
5. Ferrara, F. & Temperton, N. Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis. *Methods Protoc* **1** (2018).
6. Amanat, F. et al. A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med* (2020).
7. Tan, C.W. et al. (Research Square 2020).
8. Robbiani, D.F. et al. Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* (2020).
9. Wrapp, D. et al. Structural Basis for Potent Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies. *Cell* **181**, 1436-1441 (2020).
10. Wan, J. et al. (bioRxiv, 2020).
11. Long, Q.X. et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. *Nat Med* (2020).
12. Darnell, M.E. & Taylor, D.R. Evaluation of inactivation methods for severe acute respiratory syndrome coronavirus in noncellular blood products. *Transfusion* **46**, 1770-1777 (2006).
13. Li, Z., Michael, I.P., Zhou, D., Nagy, A. & Rini, J.M. Simple piggyBac transposon-based mammalian cell expression system for inducible protein production. *Proc Natl Acad Sci U S A* **110**, 5004-5009 (2013).
14. Tao, Y., Strelkov, S.V., Mesyanzhinov, V.V. & Rossmann, M.G. Structure of bacteriophage T4 fibrin: a segmented coiled coil and the role of the C-terminal domain. *Structure* **5**, 789-798 (1997).
15. Fairhead, M. & Howarth, M. Site-specific biotinylation of purified proteins using BirA. *Methods Mol Biol* **1266**, 171-184 (2015).
16. Pallesen, J. et al. Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. *Proc Natl Acad Sci U S A* **114**, E7348-E7357 (2017).
17. ter Meulen, J. et al. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants. *PLoS Med* **3**, e237 (2006).
18. Wang, W. et al. Chromosomal transposition of PiggyBac in mouse embryonic stem cells. *Proc Natl Acad Sci U S A* **105**, 9290-9295 (2008).
19. Shi, C. et al. Purification and characterization of a recombinant G-protein-coupled receptor, *Saccharomyces cerevisiae* Ste2p, transiently expressed in HEK293 EBNA1 cells. *Biochemistry* **44**, 15705-15714 (2005).
20. Poulain, A. et al. Rapid protein production from stable CHO cell pools using plasmid vector and the cumate gene-switch. *J Biotechnol* **255**, 16-27 (2017).
21. Stuble, M. et al. Optimization of a high-cell-density polyethylenimine transfection method for rapid protein production in CHO-EBNA1 cells. *J Biotechnol* **281**, 39-47 (2018).
22. Wang, S., Sakhatsky, P., Chou, T.H. & Lu, S. Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV). *J Immunol Methods* **301**, 21-30 (2005).
23. Russell, P.K., Nisalak, A., Sukhavachana, P. & Vivona, S. A plaque reduction test for dengue virus neutralizing antibodies. *J Immunol* **99**, 285-290 (1967).
24. Lindsey, H.S., Calisher, C.H. & Mathews, J.H. Serum dilution neutralization test for California group virus identification and serology. *J Clin Microbiol* **4**, 503-510 (1976).

25. Calisher, C.H. et al. Antigenic relationships between flaviviruses as determined by cross-neutralization tests with polyclonal antisera. *J Gen Virol* **70 ( Pt 1)**, 37-43 (1989).



**Figure 1. Establishment of a protein competition assay for neutralization of the spike-ACE2 interaction. a)** SARS-CoV-2 attachment to the host cell requires a direct interaction between the host cell receptor, ACE2 (blue), and the Receptor binding domain (RBD) of the SARS-CoV-2 spike protein. **b)** Principle of the direct binding (top right) and competition ELISA assays (bottom). Patient serum or plasma samples, monoclonal antibodies (Ab) and other affinity reagents are diluted and submitted to either a direct spike or RBD binding ELISA (detection using HRP-conjugated anti-human IgG/A/M) or the competition ELISA. The competition ELISA uses biotinylated ACE2 for the detection of the “free” RBD or spike epitopes that have not been blocked by neutralizing antibodies (using polyHRP-streptavidin). **c)** Results of the competition ELISA assay using either the RBD or the spike trimer immobilized on the plate (See **Supplementary Fig. 1-2** for the antigen cloning, expression and purification). The dashed lines are from a sample (CBS39) that was negative for direct RBD/spike binding, while the solid lines are from a positive sample (CBS50; See **Supplementary Fig. 4a** for the direct binding results and **Supplementary Table 1** for all the OD<sub>450</sub> values). **d)** Competition ELISA (immobilized RBD) for an expanded set of 4 positive controls with high anti-RBD signals in a single-point direct-binding ELISA (green), 8 negative samples acquired pre-COVID (red) and 4 samples with low anti-RBD levels (blue) (**Supplementary Fig. 4b**).



**Figure 2. Application of the competition ELISA to a larger cohort.** **a**) Representative direct-binding ELISAs with titrations on different samples from a Canadian Blood Services cohort (all ELISA curves are shown in **Supplementary Fig. 6**; see **Supplementary Fig. 7** for an extended titration of the most abundant samples). **b**) Competition ELISA results for the samples shown in **a**), see **Supplementary Fig. 8** for all curves. **c**) Correlation between the Areas Under the Curves (AUCs)



for the direct and competition ELISAs for all samples profiled (see an expanded view in **Supplementary Fig. 9**). **d**) Outliers in the correlation plot **c**) were calculated using the total least squares (TLS) method; points with a TLS > 0.4 (labelled) were marked as outliers (See **Supplementary Fig. 10** for selected examples with side-by-side direct and competition ELISAs). **e**) Results of the plaque reduction neutralization tests on the same samples overlaid on the AUC curves from **c**). Color coding indicates the PRNT50 titers while negative/positive hits on the PRNT90 assay are displayed with a different sized dot (see **Supplementary Fig. 11** for additional PRNT results and **Supplementary Fig. 12** for spike pseudotyped virus results). **f**) Assessment of the ability of monoclonal or affinity reagents to block the interaction between ACE2 and the RBD in the competition ELISA (see **Supplementary Fig. 13-16** for the direct binding and viral neutralization assays).

## Methods

### Serum and plasma samples

Canadian Blood Services Donors. Specimens-only serum donations were collected from individuals who were classified as having one or more of the following criteria: 1) self-declared evidence of a SARS-CoV-2-positive nucleic acid test, 2) a declaration of having been a close contact of a COVID-19 case, 3) a travel history and clinical presentation compatible with COVID-19, and 4) signs and symptoms compatible with COVID-19. Collections occurred two weeks or more after cessation of clinical symptoms. Serum specimens were processed as per routine laboratory processes and frozen at -80°C until shipment on dry ice to the testing laboratory.

Other samples for assay development. Negative control serum samples from patients enrolled in cancer or birth cohort studies prior to COVID-19 (prior to November 2019; REB studies #01-0138-U and #01-0347-U, Mount Sinai Hospital) and archived frozen in the LTRI Biobank were retrieved, thawed, aliquoted and transferred on ice to the research lab for viral inactivation. Alternatively, samples from previous studies of the immune system or systemic lupus acquired prior to November 2019 (REB studies #31593 University of Toronto, #05-0869, University Health Network) were transferred to the lab on dry ice. Positive controls for assay development were either convalescent plasma or serum from COVID-19 patients (confirmed by PCR; in- and out-patients) acquired in south-central Ontario in 2020 (REB studies #20-044 Unity Health Network, #02-0118-U/05-0016-C, Mount Sinai Hospital). Aliquots of these samples were transferred to the lab on dry ice. Only those samples with high levels of RBD-binding antibodies in single-point ELISA assays were considered positives for the development of the competition ELISA. Samples with low levels of RBD-binding antibodies were reclassified as “negative”.

For all ELISAs, inactivation of potential infectious viruses in plasma or serum was performed by incubation with Triton X-100 to a final concentration of 1% for 1 h prior to use<sup>12</sup>. For the pseudotyped lentiviral assays, the serum was heat-inactivated for 1 hr at 56° C<sup>6</sup>. See the different versions of the PRNT assays for details of the inactivation procedures, as applicable.

### Expression system for protein purification

The expression plasmid generated is a derivative of those previously reported in our piggyBac transposon-based mammalian cell expression system<sup>13</sup>. Two versions of the plasmid were constructed; one contains the CMV promoter (PB-CMV) and the other the TRE promoter (PB-TRE). The vectors are otherwise identical and can be used to generate stable cell lines for constitutive or inducible protein expression. The protein cloning region contains several optional elements separated by restriction sites as follows: an N-terminal human cystatin-S secretion signal, the protein of interest, a foldon trimerization motif<sup>14</sup>, a 6xHis purification tag and an AviTag biotinylation motif<sup>15</sup> (**Supplementary Fig. 1**). A woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) follows the ORF to facilitate nuclear export of the mRNA. A pair of piggyBac transposon terminal repeats flank the expression cassette and an attenuated puromycin resistance marker, thereby allowing for the generation of stable cell lines using the piggyBac transposase.

### Expression constructs for protein purification

The human codon optimized cDNA of the SARS-CoV-2 spike protein was purchased from Genscript (MC\_0101081). The human ACE2 cDNA was derived from MGC clone 47598. To stabilize the soluble spike ectodomain trimer, two regions of the spike protein were mutated. Residues 682–685 (RRAR) were mutated to SSAS to remove the furin cleavage site, and residues 986–987 (KV) were each mutated to a proline residue to stabilize the pre-fusion form as previously described<sup>16</sup>. The soluble spike protein ectodomain construct includes residues 1-1211 (MFVF...QYIK), followed by the foldon trimerization motif, a 6xHis tag and an AviTag. Both the SARS-CoV-2 receptor binding domain (RBD) and the human ACE2 constructs are preceded by the human

cystatin-S secretion signal and followed by the 6xHis and AviTag. The RBD and ACE2 constructs contain residues 328-528 (RFPN...CGPK) and 19-615 (STIE...PYAD), respectively.

The cDNA of the human CR3022 Fab fragment was synthesized by Genscript based on its previously reported sequence<sup>17</sup>. The light chain and heavy chains were individually cloned into the PB-TRE expression plasmid. For Fab production, a 6xHis tag was added to the C-terminal end of the Fab heavy chain. An IgG form was generated by fusing the human IgG1 Fc coding sequence to the C-terminal end of the Fab heavy chain.

### Large scale transient transfection

FreeStyle 293-F suspension cells were grown in shaker flasks (125 rpm) in Freestyle 293 expression medium (ThermoFisher) in a humidified 37 °C incubator filled with 3% (v/v) CO<sub>2</sub>. The cell density and viability were monitored by manual counting using a hemocytometer and trypan blue staining. For transfection, cells of >90% viability were counted and seeded at a density of approximately 10<sup>6</sup> cells/mL into 300 mL Freestyle 293 medium supplemented with 1 µg/mL Aprotinin. 300 µg of the PB-CMV plasmid DNA and 400 µL 293fectin (ThermoFisher) were each added to separate tubes containing 15 mL of Opti-MEM medium (ThermoFisher). The two solutions were then mixed and incubated for 5 min before being added to the 300 mL cell culture. Two days after transfection, the 300 mL culture was expanded into three 1L shaker flasks each containing 300 mL of culture medium. Protein expression was continued for an additional four days.

### Stable cell line generation

FreeStyle 293-F cells or a GnT1-knockout FreeStyle 293-F cell line were used for generating stable cell lines. Approximately 10<sup>6</sup> cells were added to each well of a 6-well plate in 2 mL FreeStyle 293 medium. 2 µg of the PB-TRE plasmid encoding the protein of interest, 0.5 µg of the PB-rtTA-neomycin helper plasmid<sup>13</sup> and 0.5 µg of the PBase expression plasmid, pCyL43<sup>18</sup>, were co-transfected in each well using lipofectamine 2000 (ThermoFisher) following the manufacturer's instructions. Three days post-transfection, the cells were transferred to 10-cm dishes containing FreeStyle 293 medium supplemented with 10% FBS, 2 µg/mL puromycin and 200 µg/mL G418. Selection was continued for approximately 2 weeks.

The stable cells were scaled up in 1L shaker flasks containing 300 mL FreeStyle 293 medium without supplements. When the cell densities reached approximately 10<sup>6</sup> cells/mL, 1 µg/mL doxycycline and 1 µg/mL Aprotinin were added to initiate protein expression. During the expression phase, 150 mL of the medium was removed, and fresh medium added, every other day.

### Protein purification

The harvested expression medium was centrifuged at 10,000g to remove the cells and debris. For the 6xHis tagged proteins, the clarified media were passed through an Ni-NTA column. For the spike ectodomain, 3 mL of Ni-NTA resin was used for each liter of medium. For the RBD, ACE2 and CR3022 Fab, 8 mL of Ni-NTA resin was used for each liter of medium. The Ni-NTA resin was washed with 20 column volumes of phosphate buffered saline (PBS), followed by 3–5 column volumes of PBS containing 10 mM imidazole. The protein was eluted with PBS containing 300 mM imidazole and 0.1% (v/v) protease inhibitor cocktail (Sigma, P-8849). For the CR3022 antibody, the harvested medium was incubated with rProtein A Sepharose FF resin (GE healthcare). The resin was then washed with 20 column volumes of PBS and the antibody was eluted with 50 mM glycine, pH 3.0, containing 150 mM NaCl. The acid-eluted antibody was immediately neutralized by the addition of 1/20 volume of 1 M Tris, pH 8.5. Protease inhibitor cocktail was also added to a final concentration of 0.1% (v/v). The approximate purified yields of the various proteins are as follows: RBD, 70 mg/L; spike trimer, 3 mg/L; ACE2, 50 mg/L; CR3022 Fab, 80 mg/L and CR3022 IgG, 20 mg/L.

The protein samples were stored in 40% glycerol at -12 °C. Shortly before use, the glycerol stocks were further purified using size-exclusion chromatography. For the RBD, ACE2 and CR3022 Fab/IgG, a Superdex 200 Increase (GE healthcare) column was used. For the spike ectodomain, a Superose 6 Increase (GE healthcare) column was used (**Supplementary Fig. 2**).

### Site-specific biotinylation of the AVI-tag containing proteins

Each biotinylation reaction contained 200  $\mu$ M biotin, 500  $\mu$ M ATP, 500  $\mu$ M MgCl<sub>2</sub>, 30  $\mu$ g/mL BirA, 0.1% (v/v) protease inhibitor cocktail and no more than 100  $\mu$ M of the protein-AviTag substrate. The mixture was incubated at 30 °C for 2 hr followed by size-exclusion chromatography to remove unreacted biotin. For the RBD, the degree of biotinylation was assessed using a band-shift assay. 5  $\mu$ g of the biotinylated RBD was heated to 95 °C for 30 s in SDS-PAGE loading buffer (containing 2% SDS, 50 mM DTT) and then after cooling, 1  $\mu$ L of a 5 mg/mL streptavidin solution was added. The mixture was then analyzed by SDS-PAGE to assess the formation of the RBD-streptavidin complex (**Supplementary Fig. 2**).

### Production of the VHH72 recombinant antibody

The llama single domain antibody VHH72 sequence (PDB entry 6WAQ\_1) was obtained from Wrapp *et al.*<sup>9</sup>. A cDNA encoding VHH72 fused to an ADCC-attenuated human IgG1 Fc domain (hFc1X7, from patent US 2019 352 383A1) was codon-optimized for expression in *Cricetulus griseus* (CHO cells), synthesized by Genscript and cloned into the pTT5™ plasmid<sup>19</sup>. The pTT5-VHH72hFc1X7 plasmid was transiently expressed in CHO<sup>55E1</sup> cells<sup>20</sup> using PEI-Max transfection reagent (Polysciences, Warrington, PA) and a slightly modified protocol as described previously<sup>21</sup>. The cell culture was harvested at day 7 post-transfection, centrifuged 20 min at 3000g and filter-sterilized using a 0.22  $\mu$ m membrane vacuum filter (Express PLUS, Millipore). Filtered supernatant was loaded on a 5 ml MabSelect SuRe column (GE Healthcare) equilibrated in PBS. The column was washed with PBS and the antibody eluted with 100 mM citrate buffer pH 3.6. The fractions containing the antibody were pooled and elution buffer was exchanged for PBS using NAP-25 columns (GE Healthcare). Purified VHH72hFc1X7 in PBS was quantified by absorbance at 280 nm using a Nanodrop spectrophotometer (Thermo Fisher Scientific) and the calculated extinction coefficient of the protein. Overall volumetric yield post-protein-A purification was 275 mg/L. The purified protein was analyzed by analytical size-exclusion ultra-high performance liquid chromatography coupled to a MALS detector and eluted as a major (>98% integrated area) symmetrical peak of 102 kDa with less than 2% aggregates (not shown).

### Sources of other commercial proteins and recombinant antibodies

An alternative source for RBD was BEI Resources NR-52306 (contributors F Krammer, F Amanat, S Strohmeier; lot #7034437). Commercial antibodies tested also included a human IgG chimeric antibody from Genscript (SARS-CoV-2 spike S1 Antibody (HC2001), Genscript #A02038) and two SARS-CoV-2 spike Antibodies from Active Motif (AM002414, #91349; AM001414, #91361).

### Direct ELISA assay for the identification of antibodies to the RBD

For the single point ELISAs, concentrations and incubation times were optimized to maximize the separation between anti-RBD levels in convalescent plasma or serum from that of pre-COVID era banked serum while maintaining the required levels of antigens as low as possible. One microliter of serum or plasma was used for the detection of antibodies on 96-well plates coated with 75 ng/well of recombinant purified RBD. Single point ELISAs are expressed as ratios to a positive control convalescent plasma sample. For the multipoint ELISAs, the RBD amount was fixed to 100 ng/well to match the design of the competition ELISAs, and two-fold serial dilutions of the serum or plasma sample from 1  $\mu$ L to 0.06  $\mu$ L were employed.

In both cases, the RBD antigen (diluted to 2  $\mu$ g/ml in PBS) was first adsorbed to 96-well clear Immulon 4 HBX (Thermo Scientific, #3855) plates in PBS overnight at 4 °C, then washed three times with 200  $\mu$ L PBS+ 0.1% Tween-20 (PBS-T; Sigma). Plates were blocked for 1 hr at room temperature with 200  $\mu$ L 5% Blocker™ BLOTTO (Thermo Scientific, #37530) and washed three times with 200  $\mu$ L PBS-T. In the single point ELISAs, plate blocking was performed with 3% w/v milk powder (BioShop Canada Inc., #ALB005.250, lot #9H61718) in PBS for 1–2 hr.

Patient samples (pre-treated with 1% final Triton X-100 for viral inactivation) diluted in PBS-T containing 1% w/v milk powder (1:50 for the single point ELISA) were then added to the plates and incubated for 2 hr at room

temperature (50  $\mu$ l total volume): technical duplicates were performed unless otherwise indicated. A chimeric human anti-spike antibody (SARS-CoV-2 spike S1 Antibody (HC2001), Genscript #A02038) was added to a set of wells on each plate as a serial dilution (1:5,000 to 1:80,000 or 10 ng to 0.63 ng per well in four steps) to enable cross-plate comparisons. Positive (convalescent plasma from a single patient) and negative controls (pre-COVID era banked serum) were also added to each plate, at 1  $\mu$ l.

Wells were washed three times with 200  $\mu$ l PBS-T. Goat anti-human anti-IgG (Goat anti-human IgG Fcy -HRP, Jackson ImmunoResearch, #109-035-098) at a 1:60,000 dilution (0.67 ng/well) in 1% BLOTTO was added and incubated for 1 hr. Wells were washed three times with 200  $\mu$ l PBS-T, and 50  $\mu$ l of 1-Step™ Ultra TMB-ELISA Substrate Solution (ThermoFisher, #34029) was added for 15 min at room temperature and the reaction was quenched with 50  $\mu$ l stop solution containing 0.16N sulfuric acid (ThermoFisher, #N600). The plates were read in a spectrophotometer (BioTek Instruments Inc., Cytation 3) at 450 nm. For all ELISA-based assays, raw OD values had blank values subtracted prior to analysis. For the single-point direct binding assay, the average CV across CBS samples is 3.3% (mean) and 1.8% (median) (**Supplementary Table 1**). For single point assays, all data were normalized to the positive serum control (single point) on each plate and expressed as a ratio to this control. For the multi-point dose responses, blank-adjusted reads were used.

Variations to this protocol included:

- 1) Replacement of the RBD on the plate by the BEI Resources #NR-52306. The assay was set up identically to and in parallel with our in-house produced RBD (**Supplementary Fig. 17**).
- 2) Replacement of RBD (100 ng) on plate by the spike trimer purified above (667 ng) (**Supplementary Fig. 3**).

**Competition ELISA assay for the identification of neutralizing antibodies**

Our final optimized competition ELISA assay uses 100 ng immobilized recombinant RBD on 96-well Immulon HBX plates incubated overnight at 4 °C (2  $\mu$ g/ml). All volumes added to the well were 50  $\mu$ l, unless specified otherwise. Plates are washed three times with 200  $\mu$ l PBS-T and blocked for 1-1.5 hr at room temperature with 200  $\mu$ l 3% BSA (BioShop Canada Inc. #SKI400.1, lot #9H61850). After washing as above, a four-step, two-fold serial dilution series of patient serum or plasma (0.5–4  $\mu$ l of sample) was incubated for 1 hr. The wells were washed as above, and incubated with 50 ng biotinylated recombinant ACE2 for 1 hr. After washing as above, the wells were incubated with 44 ng Streptavidin–Peroxidase Polymer (Sigma, #S2438). The resultant signal was developed and quantified with TMB in an identical manner to the direct ELISA assays. Due to day-to-day variation in signal, all OD450 values are normalized to the OD450 of the well where no patient serum/antibody was added for each sample. All values are expressed in this ratio space.

Variations of this protocol included using a different source of RBD (BEI Resources NR-52306) and using spike trimer as shown above (670ng/well) (**Fig. 1c** and **Supplementary Fig. 17**). Another variation of the assay was to bind non-biotinylated ACE2 to the plate (100 ng) and to use biotinylated RBD (50 ng) for detection (**Supplementary Fig. 3**).

**Neutralization assays**

Neutralization assays on the Canadian Blood Services samples used in **Fig. 2** were performed by two independent laboratories, the National Microbiology Laboratory of the Public Health Agency of Canada (NML), and the Wadsworth Center, New York State Department of Health (Wadsworth). The cytopathic effect-reduction neutralization assay on the recombinant Genscript antibody was performed in Toronto.

For the PRNT assay at NML, SARS-CoV-2 (Canada/ON\_ON-VIDO-01-2/2020, EPI\_ISL\_42517) stocks were titrated<sup>3</sup> for use in a plaque reduction neutralization test (PRNT) adapted from a previously described method for SARS-CoV-1<sup>22</sup>. Briefly, serological specimens were diluted 2-fold from 1:20 to 1:640 in DMEM supplemented with 2% FBS and incubated with 50 PFU of SARS-CoV-2 at 37 °C and 5% CO<sub>2</sub> for 1 hr. The sera-virus mixtures were added to 12-well plates containing Vero E6 cells at 100% confluency, followed by incubation at 37 °C and

5% CO<sub>2</sub> for 1 hr. After adsorption, a liquid overlay comprised of 1.5% carboxymethylcellulose diluted in MEM, supplemented with 4% FBS, L-glutamine, non-essential amino acids, and sodium bicarbonate, was added to each well and the plates were incubated at 37 °C and 5% CO<sub>2</sub> for 72 hr. The liquid overlay was removed and the cells were fixed with 10% neutral-buffered formalin for 1 hr at room temperature. The monolayers were stained with 0.5% crystal violet for 10 min and washed with 20% ethanol. Plaques were enumerated and compared to controls. The highest serum dilution resulting in 50% and 90% reduction in plaques compared with controls were defined as the PRNT50 and PRNT90 endpoint titers, respectively. PRNT50 titers ≥1:160 and PRNT90 titers ≥1:20 were considered positive.

For the PRNT assay at Wadsworth, the assay for the detection of SARS-CoV-2 neutralizing antibodies was a modified version of previously described methods<sup>23-25</sup>. Patient sera and SARS-CoV-2 (USA/WA-1/2020, BEI Resources, #NR-52281) were diluted in Vero E6 cell culture maintenance medium (Eagle's Minimal Essential Medium, 2% heat-inactivated fetal bovine serum, 200 U/ml Penicillin G, 200 U/ml Streptomycin). Patient samples were serially diluted 1:10 to 1:320 and mixed with an equal volume of virus containing 150 plaque forming units. Virus and serum mixtures were incubated at 37 °C and 5% CO<sub>2</sub> for 1 hr. Following the initial incubation, 0.1 mL of each dilution was plated in a single well of a 6 well plate containing confluent monolayers of Vero E6 cells (ATCC, CRL-1586) and allowed to adsorb for 1 hr at 37 °C and 5% CO<sub>2</sub>. Following adsorption, cell cultures were overlaid with 0.6% agar in cell culture medium and returned to the incubator. At two days post-infection, a second overlay containing 0.2% neutral red was added. Monolayers were inspected for two days and plaques were counted. Antibody titers were reported as the inverse of the serum dilution resulting in 50% (PRNT50) and 90% (PRNT90) reduction in plaques as compared to the virus inoculum control.

For the cytopathic effect-reduction neutralization assay in Toronto, 200 µL of 0.2x10<sup>6</sup> VeroE6 cells/mL were seeded into a 96-well flat bottom plate to adhere overnight. All plasma and serum samples were heat inactivated at 56 °C for 30 min. In a separate 96-well plate, the serum, plasma or antibody (1 µg/ml) samples were serially diluted 2-fold eight times in serum-free DMEM starting from a dilution of 1:20 to 1:2560 in a volume of 25 µL. To all wells, 25 µL of SARS-CoV-2 SB2 Clone 1 was added ensuring that each well had a dose of 100 TCID. For the cell control, 50 µL of serum free DMEM was added. For the virus control, 25 µL of SARS-CoV-2 SB2 Clone 1 was added with a dose of 100 TCID, and topped off with 25 µL of serum free DMEM. The plate was incubated for 1 hr at 37 °C, 5% CO<sub>2</sub> with shaking every 15 min. After incubation, all the media from the VeroE6 culture was removed, and the full 50 µL of serum/SARS-CoV-2 co-culture was layered on the cells. The plate was again incubated for 1 hr at 37 °C, 5 % CO<sub>2</sub>, with shaking every 15 min. After the incubation, the inoculum was removed and 200 µL of DMEM containing 2 % FBS was added. The plate was incubated for 5 days and cytopathic effect (CPE) was tracked.

### **Lentiviral spike pseudotyping assay**

The assay was established using constructs previously described<sup>4</sup> (constructs obtained through a kind gift from Jesse Bloom, Fred Hutchison Cancer Research Centre and now available through BEI Resources), and optimized in-house. Major changes to the reported protocol included: 1) Use of a 2<sup>nd</sup> generation psPAX2 (Addgene, #12260) lentivirus packaging system instead of the 3<sup>rd</sup> generation system used by the Bloom lab, 2) Production of spike pseudotyped virus-like particles (VLPs) at 33°C, 3) A neutralization assay plate layout that increases throughput, 4) Adjustments to the luciferase protocol to minimize variability in readings and, 5) Use of a cell line that co-expresses ACE2 and TMPRSS2. To generate this cell line, entry vectors for ACE2 and TMPRSS2 coding sequences were cloned into pLenti CMV Puro DEST (Addgene, #17452) and pLenti CMV Hygro DEST (Addgene, #17454) respectively. The resulting transfer vectors were used to generate lentivirus via the 2<sup>nd</sup> generation psPAX2 and VSV-G (Addgene, #8454). HEK293T cells were transduced with ACE2 lentivirus at an MOI <1 and selected with puromycin (1 µg/mL) to generate a stable population. These cells were subsequently transduced with TMPRSS2 lentivirus and selected with hygromycin (200 µg/mL) in a similar fashion.

For VLP generation, HEK293T cells were transiently co-transfected in a 6-well plate format containing 2 ml growth medium (10% FBS, 1% Pen/Strep in DMEM) with 1.3  $\mu$ g psPAX2, 1.3  $\mu$ g Luc2-IRES-ZsGreen (BEI, #NR-52516; a kind gift from Jesse Bloom) and 0.4  $\mu$ g SPIKE(fixK) (BEI, #NR-52514; a kind gift from Jesse Bloom) using 8  $\mu$ l JetPrime in 500  $\mu$ l JetPrime buffer. After 8 hr of transfection, the medium was replaced by 3 mL of DMEM containing 5% heat-inactivated FBS, 1% Pen/Strep and the cells incubated for 16 hr at 37 °C and 5% CO<sub>2</sub> and then transferred to 33 °C and 5% CO<sub>2</sub> for an additional 24 hr. At 48 hr post transfection, the supernatant was collected, spun at 500g for 5 min, filtered through a 0.45  $\mu$ m filter and frozen at -80 °C. The virus titers were evaluated using HEK293T-ACE2/TMPRSS2 cells at 10K cells per well on a Poly-L-Lysine [5-10  $\mu$ g/mL] coated 96-well plate using HI10 media (10% heat-inactivated FBS, 1% Pen/Strep) and a virus dilution resulting in >1000 relative luciferase units (RLU) over control (~1:100 virus stock dilution).

For the neutralization assay, 2.5-fold serial dilutions of the serum samples were incubated with diluted virus at a 1:1 ratio for 1 hr at 37 °C before being transferred to plated HEK293-ACE2/TMPRSS2 cells and incubated for an additional 48 hr at 37 °C and 5% CO<sub>2</sub>. After 48 hr, cells were lysed and Bright-Glo luciferase reagent (Promega, #E2620) was added for 2 min before reading with a Perkin-Elmer Envision instrument.

### **Data analysis and figure generation**

Area Under the Curve (AUC) values were tabulated for both the direct binding ELISA and the competition ELISA using R version 4.0.1 and R package pracma. For the competition ELISA, the ratios (normalized values) are used in the AUC calculations. To identify outliers, we calculated the distance of each point from the regression line using total least squares and labelled points with distances > 0.4.

For the lentiviral pseudotyping assays, 50% inhibitory concentration or dilution (IC<sub>50</sub> or ID<sub>50</sub>) were calculated with non-linear regression [log(inhibitor) vs. normalized response - Variable slope] using GraphPad Prism 8 (GraphPad Software Inc., San Diego, CA, USA).

The assay reproducibility was estimated across experiments by comparing the AUC values for those samples profiled across different batches.

CBS13 (n=3) CV for displacement was 5.1% and direct binding was 5.5%;

CBS16 (n=3) CV for displacement was 3.4% and 11.5% for binding;


CBS50 (n=2) CV for displacement was 9.9% and binding was 0.7%

### **Ethics**


All samples were collected after Research Ethics Board (REB) review. The ELISA assays were performed at the Lunenfeld-Tanenbaum Research Institutes with Mount Sinai Hospital (MSH) Research Ethics Board (REB) approval (study number: 20-0078-E). External samples were transferred through Material Transfer Agreements. All research has been performed in accordance with relevant guidelines and regulations. All participants have provided informed content. The samples were de-identified prior to transfer to the assay laboratory.

## Supplementary Figures and legends

### a Fusion protein expression




### b Layout of the PB-CMV/TRE expression plasmids




**Supplementary Figure 1. Details of the protein expression constructs.** a) Multiple cloning site and fusion tags. b) Expression vector details.







**Supplementary Figure 2. Protein purification and biotinylation.** a) Size-exclusion chromatography profiles of the RBD, ACE2 and the CR3022 Fab/IgG run on a Superdex 200 Increase column. The spike ectodomain trimer was run on a Superose 6 Increase column. Purification of the spike after the biotinylation reaction is shown to illustrate the separation of the protein from the small molecules. b) Band-shift assay to assess RBD biotinylation: lane 1, SARS-CoV-2 RBD-biotin; lane 2, SARS-CoV-2 RBD-biotin + streptavidin; lane 3, streptavidin.




**Supplementary Figure 3. A comparison of signal of the RBD-bound (forward) and ACE-bound (reverse) assays.** The forward assay (blue) is where non-labelled RBD is adsorbed onto the ELISA plate and biotinylated ACE2 is added as a probe. The reverse assay (red) is where non-biotinylated ACE2 is adsorbed and probed with biotinylated RBD. After the addition of the probing protein, the presence of the biotinylated protein is evaluated with poly-HRP and TMB.




**Supplementary Figure 4. Direct binding ELISAs for assay optimization.** a) Direct binding ELISA probing for IgG on a titration of serum samples CBS39 (negative) and CBS50 (positive). Related to Fig. 1c. b) Single-point direct binding ELISA assay of 12 pilot samples on the RBD. Data expressed as a ratio to the OD450 of a convalescent, positive plasma sample used for normalization (P1). Related to Fig. 1 c-d.




**Supplementary Figure 5. Single-point direct binding ELISA assay of all CBS samples on RBD.** Data expressed as a ratio to the OD450 of a convalescent, positive plasma sample used for normalization (P1).




**Supplementary Figure 6. The entire set of direct binding ELISAs with titrations on different samples of the Canadian Blood Services cohort.** Panels are organized by groups of behaviors in the competition ELISA (a: strong positives; b: intermediate; c: weak; d: none). Related to Fig. 2a.




**Supplementary Figure 7. An extended direct binding assay dilution series.** CBS samples exhibiting a high OD<sub>450</sub> at the lower end of the titration curve in the direct binding assay (0.06 μl) were further diluted to generate an extended direct binding titration curve. Related to Fig. 2a and Supplementary Fig. 5.




**Supplementary Figure 8. The entire set of competition assay ELISAs with titrations on different samples of the Canadian Blood Services cohort. Panels are organized on competition ELISA behaviors (a: strong positives; b: intermediate; c: weak; d: none). Related to Fig. 2b.**




**Supplementary Figure 9. Complete correlation plot between the AUCs for the direct and competition ELISAs for all samples profiled with all of the samples labelled.** Related to Fig. 2c.



**Supplementary Figure 10. ELISA results of CBS samples labelled as outliers.** a) Direct binding assay titration curves of the CBS samples with a TLS error > 0.4, and b) Competition assay titration curves of the CBS samples with a TLS error > 0.4.




**Supplementary Figure 11. PRNT50 and PRNT90 data overlaid on the AUC correlation plot.** a) The correlation curve from Fig. 2c with PRNT50 and PRNT90 data from the NML overlaid on each data point. The point fill (blue) represents the PRNT50 titre whereas the outline stroke colour (green) represents the PRNT90 titre. Grey points indicate samples that were negative with both PRNT50 and PRNT90. b) Same as panel a) but with data from Wadsworth (samples in grey were not tested). Related to Fig. 2c.




**Supplementary Figure 12. Lentiviral spike pseudotyped assay on selected CBS samples.** a) The indicated samples were tested by the lentiviral spike pseudotyped assay and the results converted to titers and overlaid on the protein-based competition assay. Related to Fig. 2c. b) Neutralization curves used to calculate the ID<sub>50</sub> values of each sample in panel a. Error bars represent the standard error of the mean (SEM).







**Supplementary Figure 13. Direct binding assay on monoclonal antibodies.** Direct binding ELISA probing for IgG on a titration of commercial monoclonal antibodies. Related to Fig. 2f.




**Supplementary Figure 14. Lentiviral spike pseudotyped assay on monoclonal antibodies.** Error bars represent the standard error of the mean (SEM).



**Supplementary Figure 15. Competition and direct binding assays of monoclonal antibodies and affinity reagents tested on our surrogate neutralization platform.** a) Competition assay of both patient samples and antibodies. b) Direct binding assay of a dilution series of serum samples and antibodies used in a). Note that the secondary antibody is an anti-Fc IgG, so the CR3022 (Fab, purple) is not expected to show activity here.



**Supplementary Figure 16. Cytopathic effect-reduction neutralization assay on the GenScript anti-spike S1 antibody.** Convalescent sera P12 and OM8086 as well as SARS-CoV-2 unexposed serum OM1 and anti-spike monoclonal antibody HC2001 were serially diluted and co-cultured with SARS-CoV-2. The co-cultures were layered onto VeroE6 cells for 1 hr and plaques were monitored. Samples were run in quadruplicates. a) neutralization dilution; b) percentage neutralization at indicated dilution.



**Supplementary Figure 17. Compatibility of the assay with the Krammer RBD antigen.** Direct binding ELISA probing for IgG on a titration of serum samples CBS39 (negative reactivity) and CBS50 (positive reactivity). Samples were run in technical duplicates.

**Supplementary tables:**  
[Supplementary Table 1](#)